Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Pharma In Focus: Pharma Stocks Dragged Down By Short Selling

|Includes: ACRX, Alexza Pharmaceuticals, Inc. (ALXA), ANTH, ASMB, HLF, KERX, MAPP, OREX

Screen Criteria:

List of Pharma stocks seeing a recent increase in short interest. (Link to original post)

Ranking of This List:

Based on performance data over the last month, this list is currently ranked 223 out of 284 lists tracked by Contextuall.com. In other words, the company characteristics described below have outperformed 21.48% of lists in Contextuall's coverage universe.

Average Weekly Returns:

Average 1-Week Return of All Stocks Mentioned Below: 1.58%

Average 1-Month Return of All Stocks Mentioned Below: 7.78%

Analysis of List Alpha:

Number of Stocks in This List Generating Excess Return vs. SP500 (Beta Adjusted Over Last Week): 5 out of 8 (62.50%)

Number of Stocks in This List Generating Excess Return vs. SP500 (Beta Adjusted Over Last Month): 2 out of 8 (25.0%)

(List sorted by monthly performance, from best to worst)

1. Alexza Pharmaceuticals Inc. (NASDAQ:ALXA): Focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Shares shorted currently at 2.42M vs. 2.18M shares shorted in the previous month (an increase in short interest representing 1.62% of total float).

2. AcelRx Pharmaceuticals (NASDAQ:ACRX): AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain in the United States and internationally. Shares shorted currently at 537.21K vs. 11.44K shares shorted in the previous month (an increase in short interest representing 6.81% of total float).

3. Keryx Biopharmaceuticals Inc. (NASDAQ:KERX): Focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Shares shorted currently at 11.53M vs. 10.53M shares shorted in the previous month (an increase in short interest representing 1.43% of total float).

4. Ventrus Biosciences Inc. (VTUS): Ventrus Biosciences, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of late-stage prescription drugs for gastrointestinal disorders primarily hemorrhoids, anal fissures, and fecal incontinence. Shares shorted currently at 1.15M vs. 987.18K shares shorted in the previous month (an increase in short interest representing 1.73% of total float).

5. Orexigen Therapeutics (NASDAQ:OREX): Focuses on the development of pharmaceutical product candidates for the treatment of obesity. Shares shorted currently at 8.79M vs. 7.74M shares shorted in the previous month (an increase in short interest representing 1.42% of total float).

6. MAP Pharmaceuticals (NASDAQ:MAPP): Focuses on the development and commercialization of inhalation therapies for patients suffering from migraine. Shares shorted currently at 5.92M vs. 4.95M shares shorted in the previous month (an increase in short interest representing 3.26% of total float).

7. Herbalife Ltd. (NYSE:HLF): Herbalife Ltd., a network marketing company, sells weight management, nutritional supplement, energy, sports and fitness, and personal care products worldwide. Shares shorted currently at 20.72M vs. 16.98M shares shorted in the previous month (an increase in short interest representing 3.52% of total float).

8. Anthera Pharmaceuticals (NASDAQ:ANTH): Focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Shares shorted currently at 9.16M vs. 8.03M shares shorted in the previous month (an increase in short interest representing 2.45% of total float).